Skip to main content
SHINIL PHARMACEUTICAL CO., LTD. logo

SHINIL PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 012790 ISIN · KR7012790002 KO Manufacturing
Open in API
Filings indexed 198 across all filing types
Latest filing 2023-03-30 Director's Dealing
Country KR South Korea
Listing KO 012790

About SHINIL PHARMACEUTICAL CO., LTD.

https://shinilpharma.com/

SHINIL PHARMACEUTICAL CO., LTD. is a drug manufacturing company that develops, produces, and sells a diverse range of pharmaceutical products. The company's portfolio encompasses various therapeutic areas, including vitamins, mineral supplements, anti-inflammatory enzymes, antihistamines, appetite stimulants, and treatments for liver disease. Its product offerings also include topical medications such as gels and medicated plasters. The company serves both domestic and international markets.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a standard regulatory requirement for insiders (directors/executives) to disclose their shareholdings and changes therein. In the provided taxonomy, this corresponds to 'Director's Dealing' (DIRS), which covers insider trades and changes in ownership by company directors and executives.
2023-03-30 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, dividend declarations, and board/auditor compensation approvals. This aligns perfectly with the definition of a Declaration of Voting Results (DVA), as it reports the official outcomes of shareholder votes at the AGM.
2023-03-27 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from Shinil Pharmaceutical titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion (which is 'unqualified' or 'proper') and key financial data (assets, liabilities, revenue, profit) for the fiscal year. According to the 'Menu vs Meal' rule, this is a short announcement (under 5,000 characters) notifying the market that the audit report has been submitted/received, rather than the full audit report document itself. Therefore, it is classified as a Report Publication Announcement (RPA). FY 2022
2023-03-17 Korean
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is titled '사업보고서' (Business Report) for the 46th fiscal year (2022.01.01-2022.12.31) for Sinil Pharmaceutical Co., Ltd. It contains comprehensive information including company overview, management, capital structure, business operations, financial data, and research activities. This is a standard Korean Annual Report (10-K equivalent). FY 2022
2023-03-17 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Shinil Pharmaceutical. It outlines the date, location, and agenda items (such as financial statement approval, dividend proposals, and board compensation). This type of document is a standard proxy solicitation/notice of meeting sent to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2023-03-10 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) issued by Sinil Pharmaceutical Co., Ltd. It contains the agenda for the 46th Annual General Meeting, including financial statement approval, director/auditor compensation limits, and voting procedures. In the context of financial filings, documents that provide notice and materials for an upcoming shareholder meeting are classified as Proxy Solicitation & Information Statements (PSI).
2023-03-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.